All Cell Therapies > Cell Therapy Card
Sign in for full access

NSI-566, spinal cord stem cells for neurological disorders

NSI-566 are human spinal cord stem cells used for treatment of amyotrophic lateral sclerosis (ALS), spinal cord injury, spinal ischemic paraplegia and chronic residual motor disorders 4-24 months following an ischemic stroke. The cells are derived from the cervical-thoracic cord of a human fetus and transplanted into the spinal cord of patients with ALS. The treatment has been proven safe. Preclinical trials in chronic ischemic stroke model in mini-pigs, resulted in effective engraftment of cells and neuronal maturation with extensive axonal projections.

A combined Phase I/II clinical trial to treat motor deficits, due to ischemic stroke, with NSI-566 cells, is planned to take place at BaYi Brain Hospital, in Beijing. A phase I, multisite clinical trial to treat acute spinal cord injury is expected to commence soon in South Korea and to treat chronic spinal cord injury, in the US, during the second half of 2013. A phase II clinical trial to treat ALS is expected to commence in the 1st quarter of 2013, at 2 sites in the US.
See additional Cell Therapies for: Brain , Motor Neurons , Spinal Cord
NSI-566, spinal cord stem cells for neurological disorders